Gina Columbus

Treatment of patients with non–small cell lung cancer should be based on the identification of rare molecular targets such as BRAF, RET, ROS1, and MET versus clinical characteristics.

The PARP inhibitor olaparib had an overall response rate of nearly 90% in a biomarker-defined subgroup of patients with metastatic castration-resistant prostate cancer who had DNA-repair defects.

Dozens of genetic abnormalities, including 44 mutated genes and 11 recurrent somatic copy number variations, were found to potentially play a role in progression and/or relapse of chronic lymphocytic leukemia.

Hans-Christian Kolberg, MD, discusses updated results from a study that showed that neoadjuvant chemotherapy with docetaxel, carboplatin, and weekly trastuzumab demonstrated significant overall survival and disease-free survival activity in patients with HER2-positive early-stage breast cancer.

Kimberly L. Blackwell, MD, discusses the potential for some emerging therapies, as well as the benefits of current treatments for patients with HER2-positive breast cancer.

Patients with hormone receptor (HR)–positive, HER2-negative breast cancer who have a favorable gene-expression profile may be able to avert chemotherapy and receive endocrine treatment alone.

David S. Ettinger, MD, discusses recent advancements in NSCLC, specifically with immunotherapy, and explains challenges that have stemmed from these developments.

Brett Miles, MD, DDS, discusses the potential of ADXS11-001 in HPV-associated head and neck cancer and other emerging therapies and treatment strategies.

Eighteen new research grants, totaling more than $19 million, have been awarded by the FDA for product development in rare diseases such as HPV-related head and neck cancer and recurrent glioblastoma.

Nivolumab (Opdivo) demonstrated clinical activity and safety in patients with platinum-resistant ovarian cancer.

The addition of bevacizumab (Avastin) to adjuvant chemotherapy did not improve overall survival in patients with surgically resected early-stage non–small cell lung cancer.

Sequence of therapies may be more significant versus single agents in treating patients with metastatic colorectal cancer.

A Giant of Cancer Care anticipates that CAR therapy will be beneficial not only in hematologic cancers, where it has proved effective, but also in solid tumors.

Patients with HER2-positive breast cancer who harbor a PIK3CA mutation are less likely to benefit from the combination of trastuzumab plus lapatinib.

To gain further insight into the impact of ibrutinib and idelalisib, as well as other emerging therapies and treatment strategies in CLL, OncLive sat down with Steven Coutre, MD, at the AACR meeting,

In an interview with OncLive, Jeffrey S. Weber, MD, PhD, discussed combinations currently in development for patients with advanced metastatic melanoma, and key considerations in employing the new therapies in clinical practice.

In an interview with OncLive, Bijal D. Shah, MD, discussed some new targeted agents for MCL and exactly how the treatment paradigm is poised to change for patients.

OncLive interviewed Jason J. Luke, MD, who discussed the clinical implications of immunotherapies in melanoma, with optimal sequencing and combinations emerging as the most pressing questions that researchers are seeking to answer in ongoing clinical trials.

Low serum neuropilin-1 may indicate longer progression-free survival with tivozanib compared with bevacizumab as a first-line treatment for patients with metastatic colorectal cancer.

For additional insight on the CLEOPATRA trial and its implications for clinical practice, OncLive interviewed Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center.

The proportion of men diagnosed with intermediate- or high-risk cancer, based on blood PSA level, increased by nearly 6% from 2011 to 2013.